Multiple myeloma: patient outcomes in real-world practice. - Wikidata - awgldk - TriplyDB

Multiple myeloma: patient outcomes in real-world practice.

Multiple myeloma: patient outcomes in real-world practice.

http://www.wikidata.org/entity/Q37394605

about

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.Living with Relapsed Myeloma: Symptoms and Self-care Strategies.The advantages of switch to subcutaneous bortezomib in the real life.Chart review across EU5 in MM post-ASCT patients Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

P2860

Q33437691-A02B4314-D6EC-44CE-B77C-678B318FBEE1 Q47198067-00CEA83B-958C-4094-9976-AEE04F4167BE Q47248893-1B00E87D-4FA5-4EFD-8476-24542AC3358D Q47269187-72CED520-FE39-47D0-ABAD-E4F7DB30556D Q49586601-FA5A0D5B-C4E7-42C7-A72F-0FDCC7EDB734 Q57301093-78BB2369-378F-4F74-B22C-E12D51180F17 Q58560605-01D71A01-82BF-4292-A9BA-B34BB43E9C6D

P2860

Multiple myeloma: patient outcomes in real-world practice.

http://www.wikidata.org/entity/Q37394605

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multiple myeloma: patient outcomes in real-world practice.

@en

Multiple myeloma: patient outcomes in real-world practice.

@nl

type

label

Multiple myeloma: patient outcomes in real-world practice.

@en

Multiple myeloma: patient outcomes in real-world practice.

@nl

prefLabel

Multiple myeloma: patient outcomes in real-world practice.

@en

Multiple myeloma: patient outcomes in real-world practice.

@nl

P1433

Q37394605-793066A1-BE7C-4782-8F99-6EBE5E64254B

P1476

Q37394605-55AA6267-2029-4F10-916A-9F3DD756F11F

P2093

Q37394605-27DA6725-99E0-446D-96D3-49B530398B1E

Q37394605-408B820E-2312-4035-A695-F1A7A541C4B9

Q37394605-7C70BE0B-DAA5-415E-91BA-7125313CCB84

Q37394605-894D7A84-212D-4465-B082-A4B811174A3F

Q37394605-99C216B9-E38F-4228-A79E-42DD9C195921

Q37394605-AA33F045-4BFA-4C79-A5AE-3D8449FF684F

Q37394605-B6E3023A-A51D-45F0-9F0A-AD77D0D058D6

Q37394605-B6FA1B0F-6D88-4D5B-B193-7170B4D3A3F3

Q37394605-BA351905-B1F6-429A-B821-66071DE7FFDB

Q37394605-C5C22FE4-15D5-4EB3-BA28-F190AB1D7E57

P2860

Q37394605-03F8932F-8B8A-4CC7-90C3-9884BFCF96FE

Q37394605-044782E2-D5D6-4BE3-A466-E2BF2A44C0FF

Q37394605-058186BB-BA6A-4B14-889C-F2348459FAA5

Q37394605-0610C4AA-0B1B-40E7-B3DE-CABB2514D494

Q37394605-13701E0B-50FD-46EF-BB8C-0E617CA6EE26

Q37394605-3566A362-191A-46F2-8A40-2B87B99C7016

Q37394605-3BE96969-45E9-41CE-9C25-9223E0215DEE

Q37394605-46D03F84-8CC6-4204-BD11-A21C1197FEEC

Q37394605-4977033F-5F4C-42FB-B527-7F1EE81C47A2

Q37394605-58CD9AC8-3BBE-418D-A7A3-6A92BBB72BBA

P304

Q37394605-A3C8373B-BC0A-457D-A773-87E0B7E45236

P31

Q37394605-B57D2557-B0C0-474B-A7F5-5671DBC4C71D

P356

Q37394605-012415C0-868B-4F0D-95A4-60DAC0748AA2

P407

Q37394605-E09756E9-18B1-46D9-BE4A-0A649DFA5694

P433

Q37394605-800D04A4-AA85-4E3D-8F05-40DA3E081DB0

P478

Q37394605-7D6AE70F-6DA2-4DCA-A080-E807183889E1

P50

Q37394605-9E5D3671-35B7-4630-B745-7DEE692FD6D5

P577

Q37394605-6EBC9569-2323-4990-A8A9-8B674DF0BB8F

P698

Q37394605-3D378EE0-B4A9-4BF0-9CA5-761415B1D6B5

P921

Q37394605-CFB60861-9F72-48F5-987D-20E887E1C466

P932

Q37394605-A7BD3B39-2B8A-47D9-BE43-DFEAE225BD5A

P356

P1433

British Journal of Haematology

P1476

Multiple myeloma: patient outcomes in real-world practice.

@en

P2093

Alain Flinois

http://www.w3.org/2001/XMLSchema#string

Christoph Driessen

http://www.w3.org/2001/XMLSchema#string

Kwee Yong

http://www.w3.org/2001/XMLSchema#string

Leah Fink

http://www.w3.org/2001/XMLSchema#string

Lionel Karlin

http://www.w3.org/2001/XMLSchema#string

Maria-Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

Michel Delforge

http://www.w3.org/2001/XMLSchema#string

Michele Cavo

http://www.w3.org/2001/XMLSchema#string

Paul Schoen

http://www.w3.org/2001/XMLSchema#string

Reza Safaei

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Antitumor activity of thalidomide in refractory multiple myeloma.

Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians.

The future of autologous stem cell transplantation in myeloma.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

International staging system for multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

P304

252-264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14213

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27411022

http://www.w3.org/2001/XMLSchema#string

P921

P932

5096152

http://www.w3.org/2001/XMLSchema#string